Specialist Updates 
Cardiology

Valsartan ‘shows promise’ in hypertrophic cardiomyopathy

A phase 2 trial suggests early treatment may attenuate cardiac remodelling.
Medicom
0
1 September 2021
Save
ClosePlease login
Box of valsartan showing its molecular structure

AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.

Use of valsartan in patients with early hypertrophic cardiomyopathy (HCM) due to a pathogenic sarcomeric gene variant attenuates markers of cardiac remodelling, a trial shows.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .